New shot aims to stop peanut allergy emergencies
NCT ID NCT07287033
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called MY006, given as a shot under the skin, to see if it can prevent severe allergic reactions from accidental peanut intake. The study involves 48 healthy volunteers and people with peanut allergies, who will receive either the drug or a placebo. Researchers will monitor safety, side effects, and how the body responds, including a food challenge with peanuts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MY006 (a drug given by injection under the skin)
- What this could lead to
- If it works, this could lead to a treatment that prevents severe allergic reactions from accidental peanut exposure, reducing the risk of life-threatening emergencies.
- What could go wrong
- This is a very early Phase 1 trial with only 48 participants, so safety and effectiveness are not yet proven. The treatment may not work or could cause side effects like injection-site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asthma and Allergy Associates, PC
RECRUITINGColorado Springs, Colorado, 809907, United States
-
Syneos Health Clinical Research Services LLC
ACTIVE_NOT_RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.